System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish 3 citations

PubMed: 38332928 DOI: 10.1002/hsr2.1871

Economic evaluation of vaccination against COVID-19: A systematic review.

Health Sci Rep 7(2):e1871

Authors: Dolatshahi Zeinab, Nargesi Shahin, Mezginejad Fateme, Bagheri Faradonbeh Saeed

Affiliations

  • Department of Health Policy, School of Health Management and Information Sciences Iran University of Medical Sciences Tehran Iran.
  • Department of Health Management and Economics, Faculty of Health Ilam University of Medical Sciences Ilam Iran.
  • Department of Hematology, School of Allied Medicine, Cellular and Molecular Research Center Birjand University of Medical Sciences Birjan Iran.
  • Department of Health Services Management, School of Health Ahvaz Jundishapur University of Medical Science Ahvaz Iran.

Abstract

Background and Aims

Coronavirus has burdened considerable expenditures on the different health systems. Vaccination programs, the critical solution against pandemic diseases, are known as safe and effective interventions to prevent and control epidemics. We aimed to perform a systematic review to provide economic evidence of the value of different types of vaccines available to combat the Covid-19 to all health policymakers worldwide.

Methods

Electronic searches conducted on Medline/PubMed, Cochrane Library, Web of Science, Scopus, Embase, and other economic evaluation databases. Related and published articles searched up to March 2022 by using keywords such as "Vaccination," "Covid-19," "Cost-benefit," "Cost-utility," "Cost-effectiveness," "Economic Assessment," and "Economic evaluation." Followed by choosing the most suitable articles according to inclusion and exclusion criteria, data captured and the results extracted. The quality assessment of the articles performed by the checklist of CHEERS 2022. Finally, 13 articles included in the review.

Results

All messenger RNA vaccines were dominant with approximately 70% coverage against no vaccination in the primary vaccination program except in one study that looked at booster effects. From a payer's perspective, a dollar invested in a vaccine would be less profitable than from a societal perspective. Therefore, primary mass vaccination can be considered a cost-effective intervention in primary vaccination to save more lives and produce more positive externalities. However, the cost-benefit ratio for all vaccines increases when statistical lifetime value and global economic and educational disadvantages are considered.

Conclusion

The COVID-19 primary vaccination programs in regional outbreaks, from a long-term perspective, will demonstrate substantial cost-effectiveness. It is suggested that due to the positive externalities of vaccination, primary mass vaccination, with the help of COVAX-19TM, could be considered a reliable way to combat viral epidemics compared to the loss of individual lives and economic and educational disturbances around the world.

MeSH

Vaccines, Vaccination, Covid-19, Mass Vaccination, Epidemics, Rna, Mrna Vaccines

Cited by